Eiger BioPharmaceuticals Stock Forecast, Price & News

-0.12 (-1.46 %)
(As of 06/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume98,267 shs
Average Volume223,597 shs
Market Capitalization$275.34 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive EIGR News and Ratings via Email

Sign-up to receive the latest news and ratings for Eiger BioPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Eiger BioPharmaceuticals logo

About Eiger BioPharmaceuticals

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. The company was founded in 2008 and is headquartered in Palo Alto, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.91 out of 5 stars

Medical Sector

128th out of 2,102 stocks

Biological Products, Except Diagnostic Industry

19th out of 198 stocks

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Eiger BioPharmaceuticals (NASDAQ:EIGR) Frequently Asked Questions

Is Eiger BioPharmaceuticals a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eiger BioPharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Eiger BioPharmaceuticals stock.
View analyst ratings for Eiger BioPharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Eiger BioPharmaceuticals?

Wall Street analysts have given Eiger BioPharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Eiger BioPharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Eiger BioPharmaceuticals' next earnings date?

Eiger BioPharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Eiger BioPharmaceuticals

How were Eiger BioPharmaceuticals' earnings last quarter?

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) announced its earnings results on Thursday, May, 6th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.51) by $0.02. The biotechnology company earned $3.65 million during the quarter, compared to analysts' expectations of $0.97 million.
View Eiger BioPharmaceuticals' earnings history

How has Eiger BioPharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Eiger BioPharmaceuticals' stock was trading at $6.81 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, EIGR stock has increased by 19.1% and is now trading at $8.11.
View which stocks have been most impacted by COVID-19

What price target have analysts set for EIGR?

2 equities research analysts have issued 1-year target prices for Eiger BioPharmaceuticals' stock. Their forecasts range from $22.00 to $28.00. On average, they expect Eiger BioPharmaceuticals' share price to reach $25.50 in the next year. This suggests a possible upside of 214.4% from the stock's current price.
View analysts' price targets for Eiger BioPharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Eiger BioPharmaceuticals' key executives?

Eiger BioPharmaceuticals' management team includes the following people:
  • Mr. David A. Cory M.B.A., R.Ph., R.Ph, MBA, Bus. Founder, Pres, CEO & Director (Age 57, Pay $1M)
  • Dr. Jeffrey S. Glenn, Founder, Scientific Advisor & Independent Director (Age 58, Pay $57.5k)
  • Mr. Sriram Ryali M.B.A., Chief Financial Officer (Age 40, Pay $567.12k)
  • Dr. Evan Loh, CEO of Paratek Pharmaceuticals & Director (Age 62, Pay $60k)
  • Mr. Eldon C. Mayer III, M.B.A., Exec. VP & Chief Commercial Officer (Age 60, Pay $657.15k)
  • Dr. Ingrid C. Choong, Sr. VP of Clinical Devel.
  • Mr. James P. Shaffer M.B.A., MBA, Chief Bus. Officer (Age 54)
  • Dr. Stephana E. Patton, Consultant (Age 50)
  • Mr. Rich Franco M.B.A., Sr. VP & Progeria Program Lead
  • Dr. Colin Hislop, Sr. VP of Clinical & Devel. Operations (Age 63)

Who are some of Eiger BioPharmaceuticals' key competitors?

What other stocks do shareholders of Eiger BioPharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger BioPharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Gilead Sciences (GILD), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Amarin (AMRN), Celldex Therapeutics (CLDX), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), SCYNEXIS (SCYX) and Sangamo Therapeutics (SGMO).

What is Eiger BioPharmaceuticals' stock symbol?

Eiger BioPharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

Who are Eiger BioPharmaceuticals' major shareholders?

Eiger BioPharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Ameriprise Financial Inc. (13.11%), BlackRock Inc. (7.40%), Geode Capital Management LLC (1.65%), Goldman Sachs Group Inc. (1.50%), Assenagon Asset Management S.A. (1.16%) and P.A.W. Capital Corp (1.12%). Company insiders that own Eiger BioPharmaceuticals stock include Eldon C Mayer III, Evan Loh, Jeffrey S Glenn and Thomas John Dietz.
View institutional ownership trends for Eiger BioPharmaceuticals

Which major investors are selling Eiger BioPharmaceuticals stock?

EIGR stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., GSA Capital Partners LLP, JPMorgan Chase & Co., Laurion Capital Management LP, Northern Trust Corp, Algert Global LLC, Citigroup Inc., and Man Group plc. Company insiders that have sold Eiger BioPharmaceuticals company stock in the last year include Eldon C Mayer III, and Evan Loh.
View insider buying and selling activity for Eiger BioPharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Eiger BioPharmaceuticals stock?

EIGR stock was acquired by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., BlackRock Inc., Renaissance Technologies LLC, Geode Capital Management LLC, Russell Investments Group Ltd., Dimensional Fund Advisors LP, Morgan Stanley, and Axiom Investment Management LLC. Company insiders that have bought Eiger BioPharmaceuticals stock in the last two years include Eldon C Mayer III, Jeffrey S Glenn, and Thomas John Dietz.
View insider buying and selling activity for Eiger BioPharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Eiger BioPharmaceuticals?

Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eiger BioPharmaceuticals' stock price today?

One share of EIGR stock can currently be purchased for approximately $8.11.

How much money does Eiger BioPharmaceuticals make?

Eiger BioPharmaceuticals has a market capitalization of $275.34 million. The biotechnology company earns $-65,050,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis.

How many employees does Eiger BioPharmaceuticals have?

Eiger BioPharmaceuticals employs 31 workers across the globe.

What is Eiger BioPharmaceuticals' official website?

The official website for Eiger BioPharmaceuticals is

Where are Eiger BioPharmaceuticals' headquarters?

Eiger BioPharmaceuticals is headquartered at 2155 PARK BOULEVARD, PALO ALTO CA, 94306.

How can I contact Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at 650-272-6138 or via email at [email protected]

This page was last updated on 6/17/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.